A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
EGFR-mutant Non-Small Cell Lung Cancer
DRUG: famitinib po|DRUG: HS-10296 po
Objective Response Rate (ORR), Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Depth of Response (DepOR), Percentage of total target lesion diameter reduced from baseline when at best overall response, From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Duration of Response (DOR), Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), From the first partial response or complete response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Disease Control Rate (DCR), Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Clinical Benefit Ratio (CBR), Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), From the start of treatment to 6 months|12-month-PFS, 12-month-progression free survival rate, From the start of treatment to 12 months|Progression-Free-Survival (PFS), Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), up to 2 years|Number of Participants with Clinically significant toxicity, Number of Participants with Clinically significant toxicity per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, First cycle (21 days)|Rate of Adverse Events and Serious Adverse Events, Rate of Adverse Events and Serious Adverse Events per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, From the first drug administration to within 30 days after the last dose
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.